CAO M D, WU R, WANG Z, et al. Varieties, indications and characteristics of Chinese patent medicines approved for marketing in China[J]. Chin Tradit Pat Med(中成药), 2019, 41(8):1999-2006
[2]
LI X L, WU Q G. Traditional Chinese Medicine Prescription Review (中药处方点评)[M]. Beijing: People's Medical Publishing House, 2017.
[3]
MA S C, WANG C, ZHU J, et al. Overall quality status of Chinese patent medicines and analysis of related problems[J]. Chin Pharm J(中国药学杂志), 2019, 54(17): 1369-1373.
[4]
XIE M, DONG L. Traditional Chinese Medicine Management(中药药事管理) [M]. Beijing: People's Medical Publishing House, 2017.
[5]
ZHANG B H, TAN L, LIANG X L, et al. Utilization analysis of TCM national essential medicines in our hospital during 2013-2015 [J]. Chin Pharm J(中国药学杂志), 2017, 52(9): 797-801.
[6]
Ch.P(2015) VolⅠ(中国药典2015年版.一部)[S]. 2015.
[7]
Chinese Pharmacopoeia Commission. Instructions for Clinical Medication in Pharmacopoeia of the People's Republic of China. Traditional Chinese Medicine Decoction Pieces Volume (2015 Edition) [中国药典临床用药须知:中药成方制剂卷(2015版)] [M]. Beijing: China Medical Science Press, 2017.
[8]
Order No. 53 of the Ministry of Health of the People's Republic of China. Prescription Administrative Policy [EB/OL]. (2007-02-14) [2021-11-12]. http://www.gov.cn/flfg/2007-03/13/content_549406.htm.
[9]
Notice on the issuance of "Management Practices of Hospital Prescription Comment (trial)" [EB/OL]. (2010-02-10) [2021-11-12]. http://www.nhc.gov.cn/wjw/yw-fw/201306/094ebc83dddc47b5a4a63ebde7224615.shtml.
[10]
National Administration of Traditional Chinese Medicine. Notice of National Administration of Traditional Chinese Medicine on issuing the Format and Writing Standards of Chinese Medicine Prescriptions [EB/OL]. (2010-10-22) [2021-11-12]. http://www.satcm.gov.cn/yizhengsi/gongzuodongtai/2018-03-24/3056.html.
[11]
The State Council of the People's Republic of China. Management Methods of Medical poisonous Drugs [EB/OL]. (1988-12-27) [2021-11-12]. http://www.nhc.gov.cn/fzs/s3576/201808/a9ae9e1fbab04a9e8c4a8ca91c037975.shtml.
[12]
Medical Administration and Hospital Administration. Notice of the General Office of the Ministry of Health on forwarding the " Special Comment Guide for Prescription of Medical Institutions of Beijing (Trial)" [EB/OL]. (2012-12-26) [2021-11-12]. http://www.nhc.gov.cn/yzygj/s3590/201212/93a34b9643bc47c5acf138228c69a60e.shtml.
[13]
National Administration of Traditional Chinese Medicine. Notice on Issuing Guidelines for Clinical Application of Chinese Patent Medicines. [EB/OL]. (2010-6-11) [2021-11-12]. http://www.satcm.gov.cn/yizhengsi/gongzuodongtai/2018-03-24/3071.html.
[14]
National Health Commission of the People's Republic of China. Notice on Further Strengthening the Production and Clinical Use Management of Chinese Medicine Injections [EB/OL]. (2008-12-24) [2021-11-12]. http://www.nhc.gov.cn/zwgk/wtwj/201304/1b6b913ef85a447bb7e83728d0aed087.shtml.
[15]
LI X L, CUI Y, CAO J L. Practical Clinical Chinese Materia Medica (Chinese patent medicine part) [实用临床中药学(中成药部分)] [M]. Beijing: People's Medical Publishing House, 2013.
[16]
T/CACM 1362-2021, China Association of Chinese Medicine. Standards for Clinical Application of Chinese Herbal Decoction Pieces [S]. 2021: 1-18.
[17]
ZHANG D F. Chinese Patent Medicines(中成药学) [M]. Beijing: China Press of Traditional Chinese Medicine, 2009.
[18]
SUN H S, QUAN S J. Clinical Prescriptions of Traditional Chinese Medicine(中药临床方剂学)[M]. Beijing: People's Medical Publishing House, 2016.
[19]
ZHANG B, ZHOU Z X. Clinical Chinese Medicine Therapeutics(临床中药药物治疗学) [M]. Beijing: People's Medical Publishing House, 2016.
2022, Vol. 57 
